| Bioactivity | Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER+/HER2+ cancer[1][2]. |
| Name | Palazestrant |
| CAS | 2092925-89-6 |
| Formula | C28H36FN3O |
| Molar Mass | 449.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12. [2]. WHO Drug Information-World Health Organization (WHO). |
Palazestrant
CAS: 2092925-89-6 F: C28H36FN3O W: 449.60
Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.